Profile data is unavailable for this security.
About the company
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
- Revenue in CHF (TTM)67.27m
- Net income in CHF22.40m
- LocationCosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
- Phone+353 18170370
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|COPN:SWX since |
|Cassiopea SpA||Announced||04 Oct 2021||04 Oct 2021Announced||-32.70%||228.73m|